09 June 2026
09 June 2026
Nuvalent’s two late-stage lung cancer assets – zidesamtinib and neladalkib – are currently under FDA review.
While the regulatory landscape around biosimilars is evolving to encourage efficiency and innovation, the commercial landscape is playing catch-up as the biosimilar void persists.
The Vega acquisition will see Incyte absorb its first-in-class bleeding disorder candidate, VG039.
The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.
NICE has preliminarily recommended D-VRd for NHS use as a first-line treatment for transplant-ineligible multiple myeloma.
Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
